核医学の世界市場2015-2022

◆英語タイトル:Nuclear Medicine - Global Market Outlook (2015-2022)
◆商品コード:SMRC60765
◆発行会社(調査会社):Stratistics MRC
◆発行日:2016年6月19日
◆ページ数:133
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥460,650見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算¥582,750見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥832,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。Stratistics MRC社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、核医学の世界市場について調査・分析し、核医学の世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。

・エグゼクティブサマリー
・序文
・核医学の世界市場:市場動向分析
・核医学の世界市場:競争要因分析
・核医学の世界市場:用途別分析/市場規模
・核医学の世界市場:タイプ別分析/市場規模
・核医学の世界市場:手術数別分析/市場規模
・核医学の世界市場:エンドユーザー別分析/市場規模
・核医学の世界市場:安定同位体別分析/市場規模
・核医学の世界市場:地域別分析/市場規模
・核医学の北米市場規模・分析
・核医学の欧州市場・分析
・核医学のアジア市場・分析
・核医学の世界市場:主な市場開拓
・関連企業分析
【レポートの概要】

According to Stratistics MRC, the Global Nuclear Medicine Market is valued at $4.42 billion in 2015 and is expected to grow at a CAGR of 10.55 % to reach $8.92 billion by 2022. Rising demand from emerging nations and the growing incidence of cardiovascular ailments and cancers are some of the key factors driving the market growth. Conversely, strict government regulations and competition from conventional diagnostic methods are hampering the market. Furthermore, technological advancements in neurological applications are anticipated to create ample of opportunities for the market in the future.
North America is the largest market in terms of revenue in 2015 due to several technological advancements within the region. However, Asia Pacific is poised to grow at a faster pace due to the increasing incidence of neurological and cardiovascular diseases and cancer. Various new products are being launched together with the several technological advancements. Thus, new product launch is the key strategy followed by the players to gain the traction in the market.

Some of the key players in global Nuclear Medicine market are Advanced Accelerator Applications S.A., Ashby Gorman Baker Ltd, Bayer Healthcare, Bracco Imaging S.P.A, Cardinal Health, Digirad, Eczcibasi-Monrol Nuclear Products, GE Healthcare, IBA Molecular Imaging, Lantheus Medical Imaging, Mallinckrodt PLC, Mediso Ltd., Nordion, Inc., Philips Healthcare and Siemens Healthcare.

Applications Covered:
• Therapeutics
o Bone Metastasis
o Endocrine Tumors
o Lymphoma
o Thyroid
o Nephrology
o Cardiology
o Neurology
o Other Therapeutic Applications
• Diagnostics
o Positron emission tomography (PET)
o Single Photon Emission Computed Tomography (SPECT)
Types of Nuclear Medicine Covered:
• Nuclear Medicine Therapeutic Isotopes
o Alpha Emitters
o Brachytherapy
o Beta Emitters
• Nuclear Medicine/Radiopharmaceuticals Diagnostics
o Positron emission tomography (PET) Radiopharmaceuticals
o Single photon emission tomography (SPECT)
Procedure Volumes Covered
• Therapeutic
o Alpha Emitters
o Beta Emitters
o Brachytherapy
• Diagnostics
o Single photon emission tomography (SPECT) Radiopharmaceuticals
o Positron emission tomography (PET) Radiopharmaceuticals
End Users Covered:
• Therapeutic
o Alpha Emitters
o Beta Emitters
o Brachytherapy
• Diagnostics
o Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
o Positron Emission Tomography (PET) Radiopharmaceuticals
Stable Isotopes Covered:
• Sulphur (S-32)
• Oxygen (O-18)
• Nitrogen (N-15)
• Deuterium (D2)
• Carbon (C-13)
• Other Stable Isotopes
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Nuclear Medicine Market, By Application
5.1 Introduction
5.2 Therapeutics
5.2.1 Bone Metastasis
5.2.2 Endocrine Tumors
5.2.3 Lymphoma
5.2.4 Thyroid
5.2.5 Nephrology
5.2.6 Cardiology
5.2.7 Neurology
5.2.8 Other Therapeutic Applications
5.3 Diagnostics
5.3.1 Positron Emission Tomography (PET)
5.3.1.1 Oncology
5.3.1.2 Neurology
5.3.1.3 Cardiology
5.3.1.4 Inflammation
5.3.1.5 Other PET Applications
5.3.2 Single Photon Emission Computed Tomography (SPECT)
5.3.2.1 Thyroid
5.3.2.2 Neurology
5.3.2.3 Lymphoma
5.3.2.4 Cardiology
5.3.2.5 Gastro Intestinal
5.3.2.6 Oncology
5.3.2.7 Nephrology
5.3.2.8 Inflammation
5.3.2.5 Other Diagnostic Applications

6 Global Nuclear Medicine Market, By Type
6.1 Introduction
6.2 Nuclear Medicine Therapeutic Isotopes
6.2.1 Alpha Emitters
6.2.1.1 Thorium-227 (Th-227)
6.2.1.2 Radium-224
6.2.1.3 Radium-223
6.2.1.4 Lead (Pb-212)/Bismuth (Bi-212)
6.2.1.5 Astatine (At-211)
6.2.1.6 Actinium (Ac-225)
6.2.1.7 Others
6.2.2 Brachytherapy
6.2.2.1 Palladium-103
6.2.2.2 Iridium-192
6.2.2.3 Iodine-125
6.2.2.4 Cesium-131
6.2.2.5 Others
6.2.3 Beta Emitters
6.2.3.1 Yttrium-90 (Y-90)
6.2.3.2 Samarium-153 (SM-153)
6.2.3.3 Rhenium-186 (Re-186)
6.2.3.4 Lutetium-177 (Lu-177)
6.2.3.5 Iodine-131 (I-131)
6.2.3.6 Erbium (Er-169)
6.2.3.7 Strontium (Sr-89)
6.2.3.8 Others
6.3 Nuclear Medicine/Radiopharmaceuticals Diagnostics
6.3.1 Positron Emission Tomography (PET) Radiopharmaceuticals
6.3.1.1 Rubidium-82 (RB-82)
6.3.1.2 Fluorodeoxyglucose (FDG)
6.3.1.3 Gallium (Ga-68)
6.3.1.4 Others
6.3.2 Single Photon Emission Computed Tomography (SPECT)
6.3.2.1 Technetium-99m (TC-99m)
6.3.2.2 Thallium-201 (TL-201)
6.3.2.3 Gallium-67 (GA-67)
6.3.2.4 Iodine (I-123)
6.3.2.5 Samarium
6.3.2.6 Yttrium
6.3.2.7 Rhenium
6.3.2.8 Others

7 Global Nuclear Medicine Market, By Procedural Volume
7.1 Introduction
7.2 Therapeutic
7.2.1 Alpha Emitters
7.2.2 Beta Emitters
7.2.3 Brachytherapy
7.3 Diagnostics
7.3.1 Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
7.3.2 Positron Emission Tomography (PET) Radiopharmaceuticals

8 Global Nuclear Medicine Market, By End User
8.1 Introduction
8.2 Academic Research Laboratories
8.3 Industries
8.4 Medical
8.4.1 Hospitals
8.4.2 Diagnostic Centers

9 Global Nuclear Medicine Market, By Stable Isotope
9.1 Introduction
9.2 Sulphur (S-32)
9.3 Oxygen (O-18)
9.4 Nitrogen (N-15)
9.5 Deuterium (D2)
9.6 Carbon (C-13)
9.7 Other Stable Isotopes

10 Global Nuclear Medicine Market, By Geography
10.1 North America
10.1.1 US
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 UK
10.2.5 Spain
10.2.6 Rest of Europe
10.3 Asia Pacific
10.3.1 Japan
10.3.2 China
10.3.3 India
10.3.4 Australia
10.3.5 New Zealand
10.3.6 Rest of Asia Pacific
10.4 Rest of the World
10.4.1 Middle East
10.4.2 Brazil
10.4.3 Argentina
10.4.4 South Africa
10.4.5 Egypt

11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling
12.1 Advanced Accelerator Applications S.A.
12.2 Ashby Gorman Baker Ltd,
12.3 Bayer Healthcare
12.4 Bracco Imaging S.P.A
12.5 Cardinal Health
12.6 Digirad
12.7 Eczcibasi-Monrol Nuclear Products
12.8 GE Healthcare
12.9 IBA Molecular Imaging
12.10 Lantheus Medical Imaging
12.11 Mallinckrodt PLC
12.12 Mediso Ltd.
12.13 Nordion, Inc.
12.14 Philips Healthcare
12.15 Siemens Healthcare

Table of Contents
1 Global Nuclear Medicine Market Outlook, By Region (2013-2022) ($MN)
2 Global Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
3 Global Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
4 Global Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
5 Global Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
6 Global Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
7 Global Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
8 Global Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
9 Global Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
10 Global Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
11 Global Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
12 Global Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
13 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
14 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
15 Global Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
16 Global Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
17 Global Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
18 Global Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
19 Global Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
20 Global Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
21 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
22 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
23 Global Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
24 Global Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
25 Global Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
26 Global Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
27 Global Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
28 Global Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
29 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
30 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
31 Global Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
32 Global Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
33 Global Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
34 Global Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
35 Global Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
36 Global Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
37 Global Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
38 Global Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
39 Global Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
40 Global Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
41 Global Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
42 Global Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
43 Global Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
44 North America Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
45 North America Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
46 North America Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
47 North America Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
48 North America Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
49 North America Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
50 North America Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
51 North America Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
52 North America Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
53 North America Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
54 North America Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
55 North America Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
56 North America Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
57 North America Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
58 North America Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
59 North America Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
60 North America Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
61 North America Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
62 North America Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
63 North America Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
64 North America Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
65 North America Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
66 North America Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
67 North America Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
68 North America Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
69 North America Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
70 North America Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
71 North America Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
72 North America Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
73 North America Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
74 North America Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
75 North America Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
76 North America Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
77 North America Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
78 North America Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
79 North America Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
80 North America Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
81 North America Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
82 North America Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
83 North America Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
84 North America Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
85 North America Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
86 North America Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
87 Europe Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
88 Europe Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
89 Europe Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
90 Europe Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
91 Europe Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
92 Europe Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
93 Europe Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
94 Europe Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
95 Europe Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
96 Europe Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
97 Europe Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
98 Europe Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
99 Europe Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
100 Europe Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
101 Europe Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
102 Europe Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
103 Europe Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
104 Europe Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
105 Europe Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
106 Europe Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
107 Europe Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
108 Europe Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
109 Europe Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
110 Europe Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
111 Europe Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
112 Europe Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
113 Europe Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
114 Europe Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
115 Europe Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
116 Europe Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
117 Europe Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
118 Europe Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
119 Europe Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
120 Europe Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
121 Europe Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
122 Europe Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
123 Europe Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
124 Europe Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
125 Europe Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
126 Europe Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
127 Europe Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
128 Europe Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
129 Europe Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
130 Asia Pacific Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
131 Asia Pacific Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
132 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
133 Asia Pacific Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
134 Asia Pacific Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
135 Asia Pacific Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
136 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
137 Asia Pacific Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
138 Asia Pacific Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
139 Asia Pacific Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
140 Asia Pacific Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
141 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
142 Asia Pacific Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
143 Asia Pacific Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
144 Asia Pacific Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
145 Asia Pacific Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
146 Asia Pacific Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
147 Asia Pacific Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
148 Asia Pacific Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
149 Asia Pacific Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
150 Asia Pacific Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
151 Asia Pacific Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
152 Asia Pacific Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
153 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
154 Asia Pacific Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
155 Asia Pacific Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
156 Asia Pacific Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
157 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
158 Asia Pacific Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
159 Asia Pacific Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
160 Asia Pacific Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
161 Asia Pacific Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
162 Asia Pacific Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
163 Asia Pacific Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
164 Asia Pacific Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
165 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
166 Asia Pacific Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
167 Asia Pacific Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
168 Asia Pacific Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
169 Asia Pacific Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
170 Asia Pacific Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
171 Asia Pacific Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
172 Asia Pacific Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
173 RoW Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
174 RoW Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
175 RoW Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
176 RoW Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
177 RoW Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
178 RoW Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
179 RoW Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
180 RoW Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
181 RoW Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
182 RoW Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
183 RoW Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
184 RoW Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
185 RoW Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
186 RoW Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
187 RoW Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
188 RoW Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
189 RoW Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
190 RoW Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
191 RoW Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
192 RoW Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
193 RoW Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
194 RoW Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
195 RoW Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
196 RoW Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
197 RoW Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
198 RoW Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
199 RoW Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
200 RoW Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
201 RoW Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
202 RoW Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
203 RoW Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
204 RoW Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
205 RoW Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
206 RoW Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
207 RoW Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
208 RoW Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
209 RoW Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
210 RoW Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
211 RoW Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
212 RoW Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
213 RoW Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
214 RoW Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
215 RoW Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)



【レポートのキーワード】

骨転移、内分泌腫瘍、ポジトロン断層法、PET

★調査レポート[核医学の世界市場2015-2022]販売に関する免責事項
★調査レポート[核医学の世界市場2015-2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆